Welcome to PsychU!

Virtual Event – Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Virtual Event – Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics

This is a Virtual Event for PsychU members in Delaware, Maryland, New Jersey, and Pennsylvania.

In this presentation, the objectives are to:

  • Understand the impact of mood episode recurrence in Bipolar I Disorder on patient functioning and clinical outcomes
  • Discuss risk factors for mood episode recurrence, including nonadherence, in patients with Bipolar I Disorder
  • Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in Bipolar I Disorder

Featuring

Salvatore G.-Savatta

Salvatore G. Savatta, MD

Chair of Psychiatry, Trinitas Regional Medical Center, Elizabeth, NJ

More
Dr. Salvatore G. Savatta received his Bachelor of Arts degree in Economics from New York University, graduated from New York University School of Medicine in 2001 and completed his M.S. in Biostatistics Clinical Research Methods at Columbia University’s Mailman School of Public Health in 2005. Dr. Savatta has previously served as Director of Inpatient Psychiatry at New York Methodist Hospital, Medical Director of TMS Centers of America and both Deputy Chair and Interim Chair of Psychiatry at Trinitas Regional Medical Center. He presently serves as Chair of Psychiatry at Trinitas and has done so since May of 2020. Dr. Savatta completed his Psychiatry Residency at St. Vincent’s Catholic Medical Center and completed a Public Service Psychiatry Fellowship and a Forensic Psychiatry Fellowship at the University of Pittsburgh Medical Center – Western Psychiatric Institute and Clinic. Dr. Savatta is Board Certified in both Adult Psychiatry and Forensic Psychiatry. He has tailored his clinical practice to focus on “difficult to treat” depression, and often includes the implementation of Neuromodulation techniques such as TMS, Esketamine, and Electroconvulsive Therapy (ECT) when clinically appropriate.
Mark-Tacelosky

Mark Tacelosky, PharmD (OPDC)

Clinical & Scientific Liaison

Speaker Salvatore G. Savatta, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Mark Tacelosky, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Join today for instant access to all PsychU content, events, and more!

Membership is free!

Name*
Specialty*
Zip / Postal Code*

Choose Your Unique Login

Your username can only contain lowercase letters (a-z) and numbers.
Email*
Password*
Your password must be at least 8 characters Hint: Must use combination of lower case letters, upper case letters, numbers and special characters like !@#$.

I AGREE TO THE FOLLOWING TERMS

I agree to the following terms:*
I agree to the following terms*
Hidden
Direct Care Provider
Hidden
Clinician Newsletter
Hidden
Management Newsletter
Hidden
user_preferences_account_notifications
Hidden
user_preferences_webinar_emails

Event Registration

MM slash DD slash YYYY
Hidden
Hidden

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS

PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.

PSYCHU MEMBERSHIP ELIGIBILITY

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.

MEMBERSHIP & REGISTRATION

Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.

ATTENDANCE LIMITATIONS

PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.

MEAL REPORTING

The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Join PsychU Today to receive a wide array of tools and benefits

  • Join our multidisciplinary community that is improving mental health care… together
  • Quickly learn more about the topics you're interested in
  • Access an award-winning library of on-demand mental health resources
  • Gain key insights from industry expert & thought leaders